公开(公告)号：US20180030151A1

公开(公告)日：2018-02-01

申请号：US15553292

申请日：2015-12-29

Applicant: MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH

Inventor： Dong-Sik KIM ,  Mi Jung LEE ,  Jae Chan PARK ,  Sumin LEE ,  Heechun KWAK ,  SungHo HWANG ,  Hyung-Kwon LIM ,  Kisu KIM ,  Young Seoub PARK ,  Junhong JEONG ,  Ki Joon CHO

IPC: C07K16/38

CPC classification number: C07K16/38 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/72 ,  C07K2317/92

Abstract: The present invention relates to an antibody that binds specifically to a tissue factor pathway inhibitor (TFPI), a nucleic acid encoding the antibody, a vector comprising the nucleic acid, a host cell transformed with the vector, a method for producing the antibody, and a pharmaceutical composition for treating hemophilia, which comprises the antibody as an active ingredient. The antibody of the present invention, which binds specifically to TFPI, can activate the extrinsic pathway of blood coagulation by inhibiting TFPI. Thus, the antibody of the present invention can be effectively used for the treatment of antibody-induced hemophilia patients and for the prevention of blood coagulation disease in hemophilia-A or hemophilia-B patients.